A Phase 2 interventional study of Capecitabine and Oxaliplatin in Rectal Cancer, sponsored by Hoffmann-La Roche. Completed at 6 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-11.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 136 studies testing capecitabine in Rectal Neoplasms — 18 open to participants now, 28 under way, 4 of them phase 3. Capecitabine · Rectal Neoplasms.
Among the 136 studies testing capecitabine in Rectal Neoplasms, this one is the 48th largest by enrollment of the 130 interventional ones that give a count, is one of 8 that started in 2005, is one of 85 in phase 2, and was the 92nd registered.
2,403 studies on the registry are indexed under Rectal Neoplasms; 589 are open to participants now.
Browse Rectal Neoplasms studies →18 of the 136 studies testing capecitabine in Rectal Neoplasms are open now, in 6 countries. Recruiting first, the newest first:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
First Affiliated Hospital of Wenzhou Medical University · Sites in China
Ages 18–75
Gruppo Oncologico del Nord-Ovest · Sites in France, Germany, Italy and 1 more country
Ages 18+
Sir Run Run Shaw Hospital · Sites in China
Ages 18–80
Sir Run Run Shaw Hospital · Sites in China
Ages 18–75
By country, each count listing its studies:
Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 406 Rectal Neoplasms studies recruiting now, 211 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
136 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 29 · Phase 2 100 · Phase 3 18 · Phase 4 2
First in 1999; this study’s year is marked. 8 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is close to the median of 65 across 1,753 interventional studies indexed under Rectal Neoplasms.
Median enrollment 49 across the 130 interventional studies. Of the 80 that completed or were terminated, 26 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 136 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 4 studies filed under Rectal Neoplasms — fewer than ten, so there is no comparison to draw.
4 of the studies testing capecitabine in Rectal Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02008656Memorial Sloan Kettering Cancer CenterTrial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management | 2026-11 |
| NCT07068763Sir Run Run Shaw HospitalNode-Sparing Short-Course Radiation Combined With Capecitabine and PD-1/CTLA-4 for MSS Early Rectal Cancer | 2026-12-31 |
| NCT01941641Chinese University of Hong KongColon Neoadjuvant FOLFOXIRI Study | 2026-12-31 |
| NCT07407465Gruppo Oncologico del Nord-OvestUpfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer. | 2027-10-20 |
Add all 4 to your calendar (.ics) → With an account.
Among the 136 studies testing capecitabine in Rectal Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the pathological complete tumor response rate.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligible participants received capecitabine 1000 milligrams per square meter (mg/m\^2) on Days 1-14, and 825 mg/m\^2 on Days 22-35 and 43-56 twice a day (bid) orally, along with oxaliplatin as a 2-hour intravenous (iv) infusion of 130 mg/m\^2/once a day (d) on Day 1 and 50 mg/m\^2/d on Days 22, 29, 43 and 50 prior to radiotherapy. Participants received radiation therapy having a fraction dose of 1.8 gray (Gy)/day, 5 days a week, for five consecutive weeks starting on Day 22 of the treatment period. Participants, who completed the treatment period, underwent surgery at Week 14.
Drug: Capecitabine · Drug: Oxaliplatin
Capecitabine is available as 50 mg and 500 mg tablets. It will be administered as a 1000mg/m\^2 bid orally on Days 1-14, and at a dose of 825mg/m\^2 bid on Days 22-35 and 43-56.
Also known as: Xeloda, Ro09-1978
Oxaliplatin is available in vials containing 50 mg or 100 mg. It will be administered as a oxaliplatin 130mg/m\^2/d intravenously on Day 1 and 50mg/m\^2/d on Days 22, 29, 43 and 50 prior to radiotherapy up to Week 9 followed by surgery period.
Also known as: Eloxatin
Percentage of Participants With Pathological Complete Tumor Response
Pathological complete tumor response was defined as grade 3 or 4 in the histological grading of regression according to Dworak classification. Grade 0 is no regression; Grade 1 is dominant tumor mass with obvious fibrosis and/or vasculopathy; Grade 2 is dominantly fibrotic changes with few tumor cells or groups; Grade 3 is defined as very few (difficult to find microscopically) tumor cells in fibrotic tissue with or without mucous substance; Grade 4 is defined as no tumor cells, only fibrotic mass (total regression or response).
Time frame: Up to Week 16
Percentage of Participants With Sphincter-preservation
Percentage of participants with sphincter-preservation is reported.
Time frame: Up to Week 16
Number of Participants With Marked Laboratory Abnormalities
Number of participants with marked laboratory abnormalities is reported.
Time frame: Up to Week 16
Percentage of Participants With Resection (R0) in Participants With T4 Rectal Cancer
R0 resection was defined as complete resection of the tumor with adequate tumor-free margins and regional lymph node extirpation as confirmed by pathology after pre-operative chemotherapy plus capecitabine + oxaliplatin therapy.
Time frame: Up to Week 16
Percentage of Participants With Downstaging of Primary Tumor and/or Lymph Nodes
Downstaging of primary tumor (T) and/or lymph nodes (N) was defined as decrease by 1 point in T-value and/or N-value (comparing at screening and after treatment). It was assessed by colonoscopy, pathology, endosonography of rectum, chest X-ray, abdominopelvic Computed Tomography and Magnetic Resonance Imaging. Staging for tumor are: TX (primary tumor cannot be assessed), T0 (no evidence of primary tumor), Tis (carcinoma in situ), T1 (tumor invades submucosa), T2 (tumor invades muscularis propria), T3 (tumor invades through muscularis propria into subserosa/into non-peritonealized pericolic/perirectal tissues, T4 (tumor directly invades other organs or structures). Staging for lymph nodes are: NX (regional lymph nodes cannot be assessed), N0 (no regional lymph node metastasis), N1 (metastasis in 1 to 3 regional lymph nodes), N2 (metastasis in 4 or more regional lymph nodes).
Time frame: From screening to Week 16
Percentage of Participants With Pathological Incomplete Tumor Response
Pathological incomplete tumor response was defined as grade 1 or 2 in the histological grading of regression according to Dworak grading of regression. Pathological incomplete tumor response rate, Grade 1: dominant tumor mass with obvious fibrosis and/or vasculopathy; Grade 2: dominantly fibrotic changes with few tumor cells or groups (easy to find) were assessed.
Time frame: Up to Week 16
Number of Participants With Any Adverse Events and Serious Adverse Events
An adverse event (AE) is defined as any untoward medical occurrence in participants or clinical investigation participants administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. A serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect.
Time frame: Up to Week 16
A total of 60 participants were enrolled in this study conducted from 30 March 2005 to 28 November 2006 at 6 centers in Switzerland.
| Milestone | Capecitabine + Oxaliplatin |
|---|---|
| Started | 60 |
| Completed | 58 |
| Not completed | 2 |
| Withdrew: Death | 1 |
| Withdrew: Withdrawal by subject | 1 |
Pathological complete tumor response was defined as grade 3 or 4 in the histological grading of regression according to Dworak classification. Grade 0 is no regression; Grade 1 is dominant tumor mass with obvious fibrosis and/or vasculopathy; Grade 2 is dominantly fibrotic changes with few tumor cells or groups; Grade 3 is defined as very few (difficult to find microscopically) tumor cells in fibrotic tissue with or without mucous substance; Grade 4 is defined as no tumor cells, only fibrotic mass (total regression or response).
| Percentage of participants | Capecitabine + Oxaliplatin |
|---|---|
| Percentage of Participants With Pathological Complete Tumor Response | 23 (13.4 to 36.0) |
Percentage of participants with sphincter-preservation is reported.
| Percentage of participants | Capecitabine + Oxaliplatin |
|---|---|
| Percentage of Participants With Sphincter-preservation | 84.48 |
Number of participants with marked laboratory abnormalities is reported.
| Participants | Capecitabine + Oxaliplatin |
|---|---|
| Hemoglobin | 7 |
| Hematocrit | 7 |
| Erythrocytes | 16 |
| Leucocytes total | 8 |
| Neutrophils | 9 |
| Basophils | 1 |
| Eosinophils | 2 |
| Monocytes | 2 |
| Lymphocytes | 42 |
| Platelets | 13 |
| ASAT/SGOT | 2 |
| ALAT/SGPT | 10 |
| Serum albumin | 3 |
| Total protein | 2 |
| Serum creatinine | 2 |
| Glucose | 13 |
| Sodium | 2 |
| Potassium | 2 |
| Calcium | 2 |
R0 resection was defined as complete resection of the tumor with adequate tumor-free margins and regional lymph node extirpation as confirmed by pathology after pre-operative chemotherapy plus capecitabine + oxaliplatin therapy.
| Percentage of participants | Capecitabine + Oxaliplatin |
|---|---|
| Percentage of Participants With Resection (R0) in Participants With T4 Rectal Cancer | 100 |
Downstaging of primary tumor (T) and/or lymph nodes (N) was defined as decrease by 1 point in T-value and/or N-value (comparing at screening and after treatment). It was assessed by colonoscopy, pathology, endosonography of rectum, chest X-ray, abdominopelvic Computed Tomography and Magnetic Resonance Imaging. Staging for tumor are: TX (primary tumor cannot be assessed), T0 (no evidence of primary tumor), Tis (carcinoma in situ), T1 (tumor invades submucosa), T2 (tumor invades muscularis propria), T3 (tumor invades through muscularis propria into subserosa/into non-peritonealized pericolic/perirectal tissues, T4 (tumor directly invades other organs or structures). Staging for lymph nodes are: NX (regional lymph nodes cannot be assessed), N0 (no regional lymph node metastasis), N1 (metastasis in 1 to 3 regional lymph nodes), N2 (metastasis in 4 or more regional lymph nodes).
| Percentage of participants | Capecitabine + Oxaliplatin |
|---|---|
| T stage | 47 |
| N stage | 48 |
| Overall | 65 |
Pathological incomplete tumor response was defined as grade 1 or 2 in the histological grading of regression according to Dworak grading of regression. Pathological incomplete tumor response rate, Grade 1: dominant tumor mass with obvious fibrosis and/or vasculopathy; Grade 2: dominantly fibrotic changes with few tumor cells or groups (easy to find) were assessed.
| Percentage of participants | Capecitabine + Oxaliplatin |
|---|---|
| Percentage of Participants With Pathological Incomplete Tumor Response | 72 (58.6 to 82.5) |
An adverse event (AE) is defined as any untoward medical occurrence in participants or clinical investigation participants administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. A serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect.
| Participants | Capecitabine + Oxaliplatin |
|---|---|
| Any AEs | 59 |
| Any SAEs | 8 |
Collected over Up to Week 16. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Capecitabine + Oxaliplatin | — | 8/60 (13.3%) | 57/60 (95%) |
| Event | Capecitabine + Oxaliplatin |
|---|---|
| DiarrhoeaGastrointestinal disorders | 5/60 |
| Abdominal PainGastrointestinal disorders | 1/60 |
| Anal HaemorrhageGastrointestinal disorders | 1/60 |
| ColitisGastrointestinal disorders | 1/60 |
| ProctitisGastrointestinal disorders | 1/60 |
| StomatitisGastrointestinal disorders | 1/60 |
| SubileusGastrointestinal disorders | 1/60 |
| SepsisInfections and infestations | 1/60 |
| Event | Capecitabine + Oxaliplatin |
|---|---|
| DiarrhoeaGastrointestinal disorders | 42/60 |
| FatigueGeneral disorders | 27/60 |
| NauseaGastrointestinal disorders | 20/60 |
| ProctitisGastrointestinal disorders | 14/60 |
| NeuropathyNervous system disorders | 13/60 |
| PollakiuriaRenal and urinary disorders | 12/60 |
| AnorexiaMetabolism and nutrition disorders | 11/60 |
| ParaesthesiaNervous system disorders | 10/60 |
| Abdominal PainGastrointestinal disorders | 8/60 |
| VomitingGastrointestinal disorders | 8/60 |
Safety population included all the participants who received at least one dose of any of the study treatments and who had a baseline assessment.
| Age, Continuous(years) | Capecitabine + Oxaliplatin |
|---|---|
| Median | 61 (35 to 77) |
| Gender(Participants) | Capecitabine + Oxaliplatin |
|---|---|
| Female | 14 |
| Male | 46 |
The record gives a start of Mar 2005, a primary completion of Aug 2006 and a completion of Nov 2006. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2016, 10 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Capecitabine · Oxaliplatin